Latest @ CSI.

View All
August 23, 2021
CSI Director Shares His Thoughts on Building a Great and Inclusive Workplace
CSI Singapore Director, Prof. Ashok Venkitaraman, recently shared his experiences and aspirations for inclusive and equitable policies and practices in the workplace during the NUHS Women in Science and Healthcare...
Read More »
August 6, 2021
CSI Singapore Receives NUS Safety & Health Commendation Award
(Top row, from left) Dr. Song Yangyang, Dr. Deepak Babu, Mr. Ng Swee Siang, Dr. Chan Jia Jia, Dr. Chen Ye, (Bottom row, from left), Ms....
Read More »

Press Release

View All
Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025)

Wan-Qin Chong, MBBS a ∙ Jia-Li Low, MBBS a ∙ Joshua K Tay, PhD b,d ∙ Thi Bich Uyen Le, BSca ∙ Grace Shi-Qing Goh, BSc g ∙ Kenneth Sooi, MBBS a ∙ Hui-Lin Teo, MBBS h ∙ Seng-Wee Cheo, MD a ∙ Regina Tong-Xin Wong, BSc g ∙ Jens Samol, MD h,j,k ∙ Ming-Yann Lim, MBBS i ∙ Hao Li, MBBS i ∙ Niranjan Shirgaonkar, MSc l ∙ Shumei Chia, PhD l ∙ Lingzhi Wang, PhD f,g ∙ Anil Gopinathan, MBBS c ∙ Donovan Kum-Chuen Eu, MBBS b ∙ Raymond King-Yin Tsang, MBChB b,d ∙ Prof Kwok-Seng Loh, MBBS b,d ∙ Prof Han-Chong Toh, MBBS m ∙ Nicholas Syn, MBBSe ∙ Li-Ren Kong, PhD f,g ∙ Ramanuj Dasgupta, PhD l ∙ Bee-Choo Tai, PhD n ∙ Yaw-Chyn Lim, PhD …

Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025) Read More »

Follow Us on Twitter

Upcoming Events

View All
×

CSI Web Experience Survey Form

Please Rate Your Satisfaction

Overall Satisfaction For This Site:
Visual Appeal:
Ease Of Finding Information:
Relevance Of Information:
Readability Of Information:
Did you accomplish what you wanted to do today on this site?